US Bancorp
PTGX icon

US Bancorp’s Protagonist Therapeutics PTGX Stock Holding History

US Bancorp’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$428K Sell
3,494
-420
-11% -$43.9K ﹤0.01% 1682
2026
Q1 		$413K Sell
3,914
-481
-11% -$42.6K ﹤0.01% 1604
2025
Q4 		$384K Sell
4,395
-1,457
-25% -$119K ﹤0.01% 1674
2025
Q3 		$389K Buy
5,852
+629
+12% +$35.8K ﹤0.01% 1649
2025
Q2 		$289K Buy
5,223
+1,569
+43% +$75.3K ﹤0.01% 1825
2025
Q1 		$177K Buy
3,654
+1,524
+72% +$63.9K ﹤0.01% 2077
2024
Q4 		$82.2K Sell
2,130
-5,736
-73% -$250K ﹤0.01% 2488
2024
Q3 		$354K Sell
7,866
-701
-8% -$28.3K ﹤0.01% 1712
2024
Q2 		$297K Buy
8,567
+2,281
+36% +$66.8K ﹤0.01% 1793
2024
Q1 		$182K Sell
6,286
-881
-12% -$24K ﹤0.01% 2057
2023
Q4 		$164K Sell
7,167
-2,743
-28% -$48K ﹤0.01% 2108
2023
Q3 		$165K Buy
9,910
+9,871
+25,310% +$192K ﹤0.01% 1913
2023
Q2 		$1.08K Buy
+39
New +$976 ﹤0.01% 3796
2022
Q4 		– Sell
-1,112
Closed -$9K – 4252
2022
Q3 		$9K Buy
+1,112
New +$10.5K ﹤0.01% 3416
2022
Q2 		– Sell
-470
Closed -$11K – 4191
2022
Q1 		$11K Buy
470
+192
+69% +$5.41K ﹤0.01% 3348
2021
Q4 		$10K Buy
278
+14
+5% +$443 ﹤0.01% 3428
2021
Q3 		$4K Sell
264
-91
-26% -$3.88K ﹤0.01% 3723
2021
Q2 		$16K Hold
355
– – ﹤0.01% 3247
2021
Q1 		$9K Sell
355
-73
-17% -$1.85K ﹤0.01% 3331
2020
Q4 		$9K Buy
428
+367
+602% +$7.9K ﹤0.01% 3231
2020
Q3 		$1K Hold
61
– – ﹤0.01% 3624
2020
Q2 		$1K Buy
+61
New +$765 ﹤0.01% 3640

Other funds holding PTGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

US Bancorp's PTGX Position: Q2 2026 in Review

US Bancorp reduced its Protagonist Therapeutics (PTGX) stake by 11% in Q2 2026, selling an estimated $43.9K and leaving 3,494 shares worth $428K. The position accounts for ﹤0.01% of the portfolio, ranked #1682.

US Bancorp first reported a position in PTGX in Q2 2020 and has held it in 22 quarters since. 343 funds tracked by Wall St. Rank hold PTGX as of Q2 2026.

  • US Bancorp held 3,494 shares of Protagonist Therapeutics worth $428K as of Q2 2026.
  • US Bancorp sold 420 Protagonist Therapeutics shares in Q2 2026, an estimated $43.9K.
  • Protagonist Therapeutics made up ﹤0.01% of US Bancorp's portfolio in Q2 2026, its #1682 holding.
  • US Bancorp first reported a position in Protagonist Therapeutics in Q2 2020 and has held it in 22 quarters since.
  • 343 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2026.

Based on US Bancorp's 13F filing for Q2 2026, filed 12 Aug 2026.